Efficacy, Tolerance, and Safety of a Novel Botanical Anti-Inflammatory Moisturizer in Rosacea: Results From a Double-Blinded, Randomized Controlled Trial.

Summary

In a 12-week double-blind RCT (n=60), a topical oat and aloe anti-inflammatory moisturizer produced significantly greater reductions in erythema (IGA) and inflammatory lesion counts than 0.75% metronidazole at Weeks 8 and 12, with no tolerability issues. Findings suggest a barrier-supportive, botanical approach can outperform a standard antibiotic cream in rosacea.

Key Findings

• At Week 8, erythema IGA reduction was 50% with the moisturizer vs 22% with metronidazole (p=0.001).
• At Week 8, inflammatory lesion counts decreased 74% with the moisturizer vs 6% with metronidazole (p=0.015).
• At Week 12, erythema IGA reduction was 54% vs 23% (p<0.001) and lesion reduction 74% vs 17% (p=0.044) favoring the moisturizer.
• No tolerability issues were reported for either product.

Clinical Implications

Consider the botanical anti-inflammatory moisturizer as a first-line or adjunct topical for mild-to-moderate rosacea, particularly to address erythema and papulopustular lesions, while reducing antibiotic exposure.

Limitations

• Single RCT with modest sample size (n=60) and 12-week duration
• Conducted in a single specialty context; generalizability and long-term relapse not assessed

Future Directions

Conduct larger, multicenter trials comparing against other standards (e.g., ivermectin, brimonidine), assess durability and relapse, and explore mechanisms of anti-inflammatory action.